Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex 4.0 mg/kg at 1–2 PTC in Normal vs Severely Impaired Renal Function
2007-006935-29Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Apr 2008
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised trial of Sugammadex (2 arms), sponsored by Organon & Co. Primary endpoint: Time to recovery of T4/T1 ratio to 0.9. Started Apr 2008; status: completed.
02
Drugs
Sugammadex
Beyond the preview
Go deeper on 2007-006935-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006935-29.